FDA center to coordinate regulatory review of cancer-related products
The Food and Drug Administration has created an Oncology Center of Excellence to coordinate and speed regulatory review of cancer drugs, biologics and medical devices as part of the administration’s Cancer Moonshot initiative. Richard Pazdur, M.D., who previously led FDA’s Office of Hematology and Oncology Products, will serve as the center’s acting director.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services has temporarily suspended certain Medicare enrollment screening requirements for health care providers that…
Headline
Health and Human Services Secretary Tom Price Friday declared public health emergencies in Georgia and South Carolina due to Hurricane Irma, and waived or…
Headline
Health and Human Services Secretary Tom Price yesterday declared a public health emergency in Florida due to Hurricane Irma, and waived or modified certain…
Headline
In a letter today to the House Ways and Means Health Subcommittee, AHA laid out actions that Congress could take to immediately reduce the regulatory burden on…
Headline
The Senate yesterday voted 94-1 to approve the FDA Reauthorization Act (H.R. 2430), sending the legislation to the president for his signature. The bill…
Headline
The Centers for Medicare & Medicaid Services yesterday issued a final rule updating Medicare’s hospice wage index, payment rates and cap amount for…